The FDA's Breakthrough Therapy Designation, established by the FDA Safety and Innovation Act’s Section 902, Expedites Development and Access to Life-Saving Drugs for Patients with Severe ...
A new global guideline for the diagnosis and treatment of Candida infections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections ...
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.
6h
Zacks.com on MSNKrystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock UpKrystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the ...
C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results